Velagliflozin: A Stand-Alone Oral Therapy for Feline Diabetes Mellitus

This webinar will explore new research in sodium-glucose cotransporter-2 (SGLT2) inhibitors, a mainstay treatment for human diabetics that holds promise for diabetic cats. Join Dr. Ellen Behrend as she discusses a prospective study that included 252 client-owned naïve diabetic (85%) or insulin-treated (15%) cats. The study revealed velagliflozin, an oral solution, to be a highly effective stand-alone therapy for feline diabetes mellitus, normalizing blood glycemic parameters and controlling clinical signs with a low overall incidence of ketoacidosis.

Not looking for CE credit for this course? You can skip entering your information below and proceed to viewing the webinar here.